InsiderSignalSign in
← Insider buys

MPM BIOVENTURES 2018, L.P. has bought stock on 2 days since Nov 2021

10% owner at Entrada Therapeutics, Inc., and 2 other companies

SEC CIK 0001729505 · Filings on SEC.gov ↗

$22.0MBought
$31.0MSold
Jan 14Last buy

MPM BIOVENTURES 2018, L.P.'s record

3 months after each buy, from the first price a copier could get.

2 buys have 3 months of prices so far. A record shows here at 3.

Companies

Every filing

22 filings since Apr 2021, newest first

TRDASell

Entrada Therapeutics, Inc.

10% owner

$1.9M−6.3%Sep 9
TRDASell

Entrada Therapeutics, Inc.

10% owner

$617K−2.0%Sep 3
TRDASell

Entrada Therapeutics, Inc.

10% owner

$616K−2.0%Aug 31
TRDASell

Entrada Therapeutics, Inc.

10% owner

$462K−1.4%Aug 27
AKTSBuy

Aktis Oncology, Inc.

10% owner

$20.0M+12.0%Jan 14
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$6.2M−5.0%Jan 6
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$2.9M−1.0%Dec 2
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$811K−1.0%Nov 30
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$2.8M−2.0%Nov 24
TRDABuy

Entrada Therapeutics, Inc.

10% owner

$2.0M+2.0%Nov 4
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$469K−1.0%Oct 18
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$1.5M−2.0%Oct 14
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$1.4M−2.0%Oct 12
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$746K−1.0%Oct 5
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$581K−1.0%Sep 30
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$1.5M−2.0%Sep 27
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$933K−1.0%Sep 23
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$2.6M−3.0%Sep 20
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$1.3M−1.0%Sep 16
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$1.6M−2.0%Sep 13
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$1.2M−1.0%Sep 8
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$777K−1.0%Apr 9
About MPM BIOVENTURES 2018, L.P.

MPM Bioventures 2018, L.P. is a Delaware-incorporated venture capital fund based in Massachusetts, operating in the biotechnology investment sector with a fiscal year end of December 31.( The firm, managed through entities like MPM BioImpact LLC at 399 Boylston Street, Suite 1100, Boston, functions as a limited partnership focused on bioventures, as evidenced by its business address in Cambridge, MA.(

As a 10% owner, MPM Bioventures 2018, L.P. has engaged in recent insider transactions at Aktis Oncology, Inc. (AKTS), including the issuance of 556,810 shares of common stock upon conversion on January 12, 2026.( It has also been reported as a 10% owner in other biotech firms such as Dyne Therapeutics Inc., underscoring its role in significant equity holdings within the industry.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.